EASTERN and growth, the inseparables
Eastern released its H1 2015/16 figures. The Egyptian leader achieved impressive results exceeding our 2015/16 profit targets. The net profit amounted to EGP809M, up by 38.1%, yoy (vs. EGP1.279bn expected by our model for the whole year). Eastern lifted its sales by 12.5% to EGP3.877bn. During the second quarter of the year, the EBITDA surged by 22.5% to reach EGP1.141bn vs. EGP932.099M by the end of December, 2014.Thus, the EBITDA margin increased significantly by 240 bps to 29.4%.EastPharma is a pharmaceutical company. Co. is engaged in the manufacture and marketing of branded and in-licensed generic pharmaceuticals in Turkey and other regional markets. Through its subsidiaries, Co. is engaged in the production and marketing of human pharmaceuticals, active pharmaceutical ingredients ("APIs") and veterinary products.
AlphaMena is the MENA stocks leader in independent equity research, covering 142. MENA securities spanning across 19 sectors and 8 countries relaying on a team of 11 analysts. The breadth of coverage allows AlphaMena to formulate a coherent view on markets, sectors and to highlight the best investments in Mena zone using a robust homogeneous and transparent methodology, enabling pure and pertinent comparisons based on financial and extra-financial criteria.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.